Literature DB >> 12628309

Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes.

Thomas A Kocarek1, Sarita D Shenoy, Nancy A Mercer-Haines, Melissa Runge-Morris.   

Abstract

INTRODUCTION: To determine the feasibility of using dominant negative nuclear receptors to dissect the regulation of inducible gene expression in primary cultured hepatocytes, a series of dominant negative nuclear receptor expression plasmids were designed with truncated AF-2 subdomains.
METHODS: Plasmids expressing dominant negative or wild-type constitutive androstane receptor (CAR), pregnane X receptor (PXR), farnesoid X receptor (FXR), liver X receptor (LXR), or peroxisome proliferator-activated receptor alpha (PPARalpha) were transiently cotransfected into primary cultured rat hepatocytes, together with an appropriate reporter plasmid.
RESULTS: Treatment with prototypic inducers, 10(-4) M phenobarbital (CAR activator), 10(-5) M pregnenolone 16alpha-carbonitrile (PXR activator), 3x10(-5) M chenodeoxycholate (FXR activator), or 10(-4) M ciprofibrate (PPARalpha activator), significantly activated expression from the corresponding reporter plasmid. Treatment with 22(R)-hydroxycholesterol (LXR activator) only weakly activated the LXR-responsive reporter, while pregnenolone 16alpha-carbonitrile treatment significantly activated this reporter. Cotransfection with wild-type LXRalpha strongly enhanced 22(R)-hydroxycholesterol-inducible expression from the LXR-responsive reporter. Cotransfection of hepatocyte cultures with each of the dominant negative nuclear receptor plasmids significantly inhibited inducible expression of the corresponding reporter while, with one exception (LXRalpha), cotransfection with the wild-type receptor moderately enhanced or had little effect on reporter expression. When each dominant negative nuclear receptor was cross-examined against all inducer-reporter pairs, effects on multiple inducer-reporter pairs were frequently observed. However, in general, only cotransfection with the appropriate dominant negative inhibited inducible reporter expression to a greater extent than did cotransfection with the corresponding wild-type receptor. DISCUSSION: We suggest that the application of dominant negative nuclear receptors has utility in transient transfection studies aimed at discerning the regulatory role of individual nuclear receptor transcription factors in inducible hepatic gene expression, provided that appropriate controls are employed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12628309     DOI: 10.1016/S1056-8719(03)00002-9

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  8 in total

1.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Authors:  C Giordano; S Catalano; S Panza; D Vizza; I Barone; D Bonofiglio; L Gelsomino; P Rizza; S A W Fuqua; S Andò
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

2.  Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.

Authors:  Shinobu Miyazaki-Anzai; Moshe Levi; Adelheid Kratzer; Tabitha C Ting; Linda B Lewis; Makoto Miyazaki
Journal:  Circ Res       Date:  2010-04-29       Impact factor: 17.367

3.  Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells.

Authors:  Stefania Catalano; Rocco Malivindi; Cinzia Giordano; Guowei Gu; Salvatore Panza; Daniela Bonofiglio; Marilena Lanzino; Diego Sisci; Maria Luisa Panno; Sebastiano Andò
Journal:  J Biol Chem       Date:  2009-12-21       Impact factor: 5.157

4.  Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine.

Authors:  Jiang Li; Annette Wilson; Xiang Gao; Ramalinga Kuruba; Youhua Liu; Samuel Poloyac; Bruce Pitt; Wen Xie; Song Li
Journal:  J Pharmacol Exp Ther       Date:  2009-07-15       Impact factor: 4.030

5.  Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.

Authors:  P Martin; R Riley; D J Back; A Owen
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

6.  Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress.

Authors:  Karen E Swales; Rick Moore; Nicola J Truss; Arthur Tucker; Timothy D Warner; Masahiko Negishi; David Bishop-Bailey
Journal:  Cardiovasc Res       Date:  2011-12-13       Impact factor: 10.787

7.  Activated FXR Inhibits Leptin Signaling and Counteracts Tumor-promoting Activities of Cancer-Associated Fibroblasts in Breast Malignancy.

Authors:  Cinzia Giordano; Ines Barone; Valentina Vircillo; Salvatore Panza; Rocco Malivindi; Luca Gelsomino; Michele Pellegrino; Vittoria Rago; Loredana Mauro; Marilena Lanzino; Maria Luisa Panno; Daniela Bonofiglio; Stefania Catalano; Sebastiano Andò
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

8.  The evolution of drug-activated nuclear receptors: one ancestral gene diverged into two xenosensor genes in mammals.

Authors:  Christoph Handschin; Sharon Blättler; Adrian Roth; Renate Looser; Mikael Oscarson; Michel R Kaufmann; Michael Podvinec; Carmela Gnerre; Urs A Meyer
Journal:  Nucl Recept       Date:  2004-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.